Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials

Efficacy and Adverse Effects of Ginkgo Biloba for Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis

(2018) Meng-Shan Tan et al.   JOURNAL OF ALZHEIMERS DISEASE

Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis

(2018) Chen-Chen Tan et al.   JOURNAL OF ALZHEIMERS DISEASE

Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis

(2017) Taro Kishi et al.   JOURNAL OF ALZHEIMERS DISEASE

Dementia prevention, intervention, and care

(2017) Gill Livingston et al.   LANCET

Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials

(2016) Ludovic Trinquart et al.   ANNALS OF INTERNAL MEDICINE

Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease

(2016) William James Deardorff et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)

(2016) Martin Knapp et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance

(2015) J.-H. Lee et al.   ACTA NEUROLOGICA SCANDINAVICA

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

(2015) R. Schmidt et al.   EUROPEAN JOURNAL OF NEUROLOGY

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses

(2015) Robert Howard et al.   LANCET NEUROLOGY

Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer’s Dementia

(2014) James E. Frampton   DRUGS & AGING

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model.

(2014) M Bond et al.   HEALTH TECHNOLOGY ASSESSMENT

Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis

(2014) Jun Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines

(2013) Jeffrey L. Cummings et al.   CNS Neuroscience & Therapeutics

Evaluation of inconsistency in networks of interventions

(2013) A. A. Veroniki et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

(2012) Serge Gauthier et al.   Alzheimers & Dementia

Drug repositioning for Alzheimer's disease

(2012) Anne Corbett et al.   NATURE REVIEWS DRUG DISCOVERY

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neuropsychiatric symptoms in Alzheimer’s disease

(2011) Constantine G. Lyketsos et al.   Alzheimers & Dementia

The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease

(2010) Jaclyn Cappell et al.   CNS DRUGS

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimerʼs Disease

(2010) Denis Getsios et al.   PHARMACOECONOMICS

Checking consistency in mixed treatment comparison meta-analysis

(2010) S. Dias et al.   STATISTICS IN MEDICINE